- GE, Comcast Agree on NBC Universal Valuation: Report
- BofA Board in Civil War Over Lewis' Succesor
- For the Jobless, 10% is Harder Than Before
- Week Ahead: Stocks Search for Catalyst in Quiet Week
- Outlook: Dollar to Ride Higher on Bleak Jobs Report
- Geithner: More Stimulus, Not a Bank Tax
- Windfall is Seen as Bank Bonuses are Paid in Stock
- Volatility Returns: Sign of the Bull Losing Muscle?
- Cramer: Earnings, IPOs Dominate Next Week
- Tamminen: Why Does Oklahoma Want To Drown New York?
- Food Network, HGTV Drive Scripps Networks' Upside Surprise
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Stock volatility is back, a sign of an aging bull?
- Precision Machine opening plant in Sturgis, SD
- NM auto dealer tried to save business by gambling
- Northrop sells advisory services unit for $1.65B
- Christmas comes early: ‘Carol’ tops box office
- Philly transit strike in 6th day; no new talks
- Obama says it's now Senate's turn on health care
- Dubai says it has repaid $1 billion aviation bond
- Indian PM hopes for 7 percent growth next year
WASHINGTON - Want to know your entire DNA sequence? A California company has done it for as little as $1,700.
Privately held Complete Genomics says it can do a better quality, usable genome map for about $4,400 -- compared with the $100 million the Human Genome Project spent to complete the first sequencing of the human genome in 2000.
"Whole-genome sequencing costs have dropped from the more than $100 million cost of the first human genomes to the point where individual labs have generated genome sequences in a matter of months for material costs of as low as $48,000," the company's Radoje Drmanac and colleagues reported in the journal Science.
"This high-quality, cost-effective approach to genome sequencing will allow researchers to study complete genomes from hundreds of patients with a disease to advance the understanding of the genetic causes of that disease, with an end to preventing and treating common human ailments," said Cliff Reid, chief executive officer of Complete Genomics.
Two of the people whose DNA was mapped had taken part in an international sequencing project called the International HapMap project -- a man of European descent and a Yoruban female.
The third came from a white man taking part in the Personal Genome Project, an online registry in which people are asked to donate both their DNA and a little money.
Genome sequencing is still early stage science. While researchers can get the code, figuring out what it means is a different matter.
Genomics pioneer Craig Venter had his own genome sequenced -- at a cost of "several million" dollars -- and found the analysis could only show he was likely to have blue eyes, for instance. Venter does have blue eyes.
Last month Pauline Ng of the J. Craig Venter Institute in San Diego and Sarah Murray of Scripps Translational Science Institute in La Jolla, California, tested kits provided by California-based firms Navigenics Inc, a private company, and 23andMe, backed by Google Inc.
They found they varied in predicting disease risk.
Complete Genomics and The Institute for Systems Biology said earlier this week they plan to sequence the genomes of 100 people to try and find insights into Huntington's disease.
Scientists also use a technique called genome-wide association to try to find genes that no one suspected were involved in various diseases.
- Rumors abound that Oprah will leave her show to start a new network. What would this mean for daytime TV?
- A private equity specialist sponsored a stand-up comedy troupe in New York to prove that CEOs can, in fact, be funny.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- Did Hideki Matsui’s performance make it more likely that the Yankees will pay to have him back?
- Which wines should you bring—or serve—with holiday meals this year? Ask a connoisseur.
- Two competitors in this year’s World Series of Poker in Las Vegas have stories fit for Hollywood.









